Wednesday, March 10
Lecture Time: 12:45 - 13:00
Live Discussion: 17:00 - 17:30
Cerebrospinal Fluid Biomarker Concordance with Amyloid PET in EMERGE/ENGAGE, Phase 3 Studies of Aducanumab in Patients with Early Alzheimer s Disease
Session: Aβ Targeting Therapies in AD 2
Saturday, March 13
Lecture Time: 12:45 - 13:00
Live Discussion: 17:30 - 18:00
Evaluation of Aducanumab Efficacy in Early Alzheimer s Disease.
Session: Aβ Targeting Therapies in AD 2
Saturday, March 13
Lecture Time: 13:00 - 13:15
Live Discussion: 17:30 - 18:00
Evaluation of Aducanumab Safety in Early Alzheimer s Disease.
This release discusses investigational uses of agents in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such investigational agents will successfully complete clinical development or gain health authority approval.
Eisai Alzheimer s Disease Pipeline Research to be Presented at Virtual AD/PD™ 2021, Including Lecanemab (BAN2401) Data
- Oral presentations and posters highlighting Eisai s investigational novel therapies and immunoassay system being studied for Alzheimer s disease and its clinical symptoms
- Preliminary analyses evaluating brain amyloid beta reduction with lecanemab to be featured in oral presentation
- Virtual symposium: The Science Behind the Aβ Pathway in Alzheimer s Disease
News provided by
Share this article
Share this article
WOODCLIFF LAKE, N.J., March 5, 2021 /PRNewswire/ Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today the presentation of data and information from the company s robust Alzheimer s disease (AD) pipeline, including lecanemab (BAN2401). Jointly developed by Eisai and Biogen Inc., lecanemab is an investigational humanized monoclonal antibody that binds to neutralize and eliminate soluble, toxic amyloid beta (Aβ) ag